key: cord-0823505-q6joumj2
authors: D'Errico Ramirez, A.; Giovannico, L.; Parigino, D.; Capone, G.; Lionetti, G.; Santeramo, V.; Fischetti, G.; Ursi, R.; Civita, A.; Grasso, S.; Milano, A.
title: Cardiogenic Shock in COVID 19 Fulminant Myocarditis Treated with V-A ECMO
date: 2022-04-30
journal: The Journal of Heart and Lung Transplantation
DOI: 10.1016/j.healun.2022.01.679
sha: 4964ec63d7edac272d825b712919714e4ba0e1ef
doc_id: 823505
cord_uid: q6joumj2

Introduction As COVID-19 pandemic spread, cases of involvement of the heart have been reported. Case Report A 47-year-old woman was admitted to the ICU of our hospital for severe cardiogenic shock. She was pyretic, hypoxemic, tachycardic and with reduction of voltages at ECG. TTE showed severe biventricular impairment with an EF of 20 %. Chest X-ray revealed interstitial edema (Fig.1). Invasive mechanical ventilation and inotropic support and empiric antibiotic therapy were set up. High levels of IL-6, lactate, TpnI, and pro-BNP and WBC emerged from laboratory exams (Fig.2).Testing for cardiotropic viruses came back negative, as well as hemocultures. BAL PCR resulted positive for SARS-CoV2. COVID-19 myocarditis was therefore diagnosed. Due to severe hypotension irresponsive to noradrenaline and adrenaline, IABP was placed. The following day, a pericardiocentesis was carried out for cardiac tamponade. Due to worsening of the general conditions, V-A ECMO was implanted. Corticosteroids were administered at high dosage. As cardiac function steadily improved and pro BNP and troponins decreased, vasopressor and inotrope were stopped, V-A ECMO was removed and IABP support was interrupted. Improvement of biventricular function was observed (EF 55 %), after 15 days the patient was transferred to the ward and after 25 days was discharged with heart failure therapy. Summary Currently, most of the ongoing research focuses on the respiratory complication of SARS-CoV2 and little is known about the management of COVID-19 myocarditis. In our experience, high dosage glucocorticoids, inotropes, and V-A ECMO improved the clinical conditions of the patient.

2017 to 28.6% (30/105) in 2020. Successful transplantation occurred in 75% (49/65) patients bridged with Impella and 68.9% (53/77) bridged with IABP (p=0.39). Among transplanted patients, several baseline characteristics differed between the Impella and IABP groups, including longer device duration, more pre-transplant packed red blood cell (PRBC) transfusions, and more multi-organ transplants in Impella patients (all p<0.05). At 6 months, post-transplant survival and stroke rates were similar (both p>0.5). In patients bridged with IABP, rates of rejections trended lower, while rates of CAV and NF-MACE were numerically higher, primarily driven by higher rates of pacemaker implant (Table) Conclusion: The use of IABP and Impella 5.0/5.5 as BTT is increasing, with excellent 6-month survival. Registry analysis may help quantify the impact of increased blood product and induction therapy requirement associated with Impella 5.0/5.5 use Cardiology, Policlinico of Bari, Bari, Italy; and the 3 Anesthesiology, Policlinico of Bari, Bari, Italy.

Introduction: As COVID-19 pandemic spread, cases of involvement of the heart have been reported. Case Report: A 47-year-old woman was admitted to the ICU of our hospital for severe cardiogenic shock. She was pyretic, hypoxemic, tachycardic and with reduction of voltages at ECG. TTE showed severe biventricular impairment with an EF of 20 %. Chest X-ray revealed interstitial edema (Fig.1) . Invasive mechanical ventilation and inotropic support and empiric antibiotic therapy were set up. High levels of IL-6, lactate, TpnI, and pro-BNP and WBC emerged from laboratory exams (Fig.2) .Testing for cardiotropic viruses came back negative, as well as hemocultures. BAL PCR resulted positive for SARS-CoV2. COVID-19 myocarditis was therefore diagnosed. Due to severe hypotension irresponsive to noradrenaline and adrenaline, IABP was placed. The following day, a pericardiocentesis was carried out for cardiac tamponade. Due to worsening of the general conditions, V-A ECMO was implanted. Corticosteroids were administered at high dosage. As cardiac function steadily improved and pro BNP and troponins decreased, vasopressor and inotrope were stopped, V-A ECMO was removed and IABP support was interrupted. Improvement of biventricular function was observed (EF 55 %), after 15 days the patient was transferred to the ward and after 25 days was discharged with heart failure therapy. Summary: Currently, most of the ongoing research focuses on the respiratory complication of SARS-CoV2 and little is known about the management of COVID-19 myocarditis. In our experience, high dosage glucocorticoids, inotropes, and V-A ECMO improved the clinical conditions of the patient. Introduction: Infections in LVAD-patients are common and may lead to life-threatening complications. Although driveline infections are most commonly detected, development of blood stream infections related to LVAD-implantation can also pilot towards mediastinitis and osteomyelitis, thus resulting in extensive bone destruction of the sternum. Case Report: A 37-year-old patient was transferred to our heart failure unit following complete sternectomy due to severe osteomyelitis, mediastinitis and a pyopericardium three years after an emergent LVAD implantation. An LVAD weaning was not possible due to immediate compromise of hemodynamics. The patient presented a thorax apertum secured in vacuum therapy and persistent wound infection with 3 MRGN positivity. Through intensified antibiotic therapy, continuous wound dressing and renewal of vacuum therapy, the infection was controlled, and a stable status achieved. After excluding contraindications for heart transplantation (HTx), the patient was accepted for a high-urgency transplantation and successfully transplanted one month later. Thereupon, the thorax was surgically reconstructed using an extended, right-sided latissimus-dorsi, myo-cutaneous flap. Relevant hemorrhage and partial repositioning of the flap was surgically approached two weeks after the initial procedure. Antibiotic treatment was continued to prevent superinfection and modified due to postoperative pneumonia and coloproctitis. The latissimus plastic showed continuous serous perfusion without inflammation, which was drained once weekly in an external clinic for two months. Echocardiography showed preserved biventricular function. Myocardial biopsies detected no higher-grade rejection as immunosuppression was established. After achieving full recovery, the patient was successfully discharged. Summary: Extended and undetected osteomyelitis can rapidly lead to lifethreatening mediastinitis and sepsis. Whenever inflammation parameters remain elevated, osteomyelitis should always be considered as a focus of infection on patients following LVAD-implantation. A combined heart transplantation and latissimus-dorsi plastic present a viable option for defect coverage and a possible long-term solution after extensive sternal resection in LVAD patients.

Purpose: Recent studies reported poor to moderate humoral response after 2 vaccine doses in heart transplant recipients (HTR). Currently, French authorities recommend 2 and 3 vaccine injections for transplant recipients with and without prior SARS-CoV-2 infection, respectively. This study aimed to evaluate level and durability of humoral immunity with this vaccination strategy. Methods: This single-center cohort study included HTR followed at Paris Bichat hospital between

Only half seroconverters HTRn reached the 260 BAU/mL cut-off chosen by French authorities to define vaccination efficacy. Interestingly, these patients seem to have a sustained humoral response 4 months after the 3 rd dose. Conclusion: This study gives new insights on the effect of the 3 rd vaccine dose in HTR with low rate of seroconversion and low titers of anti-S IgG but sustained humoral response when seroconversion occurs